NO332262B1 - Fremgangsmate for fremstilling av piroxicam: beta-cyklodekstrin-inklusjonsforbindelser - Google Patents
Fremgangsmate for fremstilling av piroxicam: beta-cyklodekstrin-inklusjonsforbindelser Download PDFInfo
- Publication number
- NO332262B1 NO332262B1 NO20040601A NO20040601A NO332262B1 NO 332262 B1 NO332262 B1 NO 332262B1 NO 20040601 A NO20040601 A NO 20040601A NO 20040601 A NO20040601 A NO 20040601A NO 332262 B1 NO332262 B1 NO 332262B1
- Authority
- NO
- Norway
- Prior art keywords
- temperature
- piroxicam
- solution
- drying
- cyclodextrin
- Prior art date
Links
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229960002702 piroxicam Drugs 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 38
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 25
- 150000001875 compounds Chemical class 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000008569 process Effects 0.000 title abstract description 10
- 239000001116 FEMA 4028 Substances 0.000 title abstract 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 title abstract 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 title abstract 2
- 229960004853 betadex Drugs 0.000 title abstract 2
- 238000001035 drying Methods 0.000 claims abstract description 15
- 230000008014 freezing Effects 0.000 claims abstract description 14
- 238000007710 freezing Methods 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 13
- 238000004108 freeze drying Methods 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000908 ammonium hydroxide Substances 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 239000007864 aqueous solution Substances 0.000 abstract description 3
- 229960000074 biopharmaceutical Drugs 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 19
- 238000004090 dissolution Methods 0.000 description 10
- 229940097362 cyclodextrins Drugs 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000005496 eutectics Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000005280 amorphization Methods 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000010668 complexation reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010065016 Post-traumatic pain Diseases 0.000 description 2
- 238000001237 Raman spectrum Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 238000005079 FT-Raman Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010036313 Post-traumatic headache Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- -1 cyclic oligosaccharides Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 238000003836 solid-state method Methods 0.000 description 1
- 238000010671 solid-state reaction Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02013251A EP1374906B1 (fr) | 2002-06-17 | 2002-06-17 | Procédé pour la préparation des composés d'inclusion piroxicam: beta-cyclodextrine |
| PCT/EP2003/006142 WO2003105906A1 (fr) | 2002-06-17 | 2003-06-12 | Procede pour preparer des composes d'inclusion de piroxicam:b-cyclodextrin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20040601L NO20040601L (no) | 2004-02-10 |
| NO332262B1 true NO332262B1 (no) | 2012-08-13 |
Family
ID=29716770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20040601A NO332262B1 (no) | 2002-06-17 | 2004-02-10 | Fremgangsmate for fremstilling av piroxicam: beta-cyklodekstrin-inklusjonsforbindelser |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7700579B2 (fr) |
| EP (2) | EP1374906B1 (fr) |
| KR (1) | KR101079484B1 (fr) |
| CN (1) | CN100352444C (fr) |
| AT (1) | ATE359827T1 (fr) |
| AU (1) | AU2003245931A1 (fr) |
| CA (1) | CA2489708A1 (fr) |
| CY (1) | CY1107693T1 (fr) |
| DE (1) | DE60219609T2 (fr) |
| ES (1) | ES2286177T3 (fr) |
| HK (1) | HK1080720A1 (fr) |
| HR (1) | HRP20041192B1 (fr) |
| IL (1) | IL165797A0 (fr) |
| JO (1) | JO2533B1 (fr) |
| MA (1) | MA27367A1 (fr) |
| MX (1) | MXPA04012502A (fr) |
| MY (1) | MY134691A (fr) |
| NO (1) | NO332262B1 (fr) |
| PL (1) | PL218414B1 (fr) |
| PT (1) | PT1374906E (fr) |
| RU (1) | RU2316350C2 (fr) |
| SA (1) | SA03240220B1 (fr) |
| SI (1) | SI1374906T1 (fr) |
| TN (1) | TNSN04245A1 (fr) |
| TW (1) | TWI341731B (fr) |
| WO (1) | WO2003105906A1 (fr) |
| ZA (1) | ZA200410142B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2876911B1 (fr) * | 2004-10-21 | 2007-04-13 | Pierre Fabre Medicament Sa | Complexe comprenant du piroxicam, une cyclodextrine et de l'arginine |
| RU2382654C2 (ru) | 2004-04-01 | 2010-02-27 | Пьер Фабр Медикаман | Комплексы включения, полученные способом с использованием co2 в сверхкритическом состоянии и агента взаимодействия с комплексом |
| FR2868315B1 (fr) * | 2004-04-01 | 2006-07-14 | Pierre Fabre Medicament Sa | Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique |
| CN101002782B (zh) * | 2007-01-10 | 2010-05-19 | 南京师范大学 | 含有头孢呋辛酯环糊精包合物的药物组合物及其制备方法 |
| CN101264087B (zh) * | 2007-03-14 | 2010-10-27 | 南京师范大学 | 含有头孢泊肟酯环糊精包合物的药物组合物及其制备方法 |
| BR112013002734A2 (pt) | 2010-08-04 | 2016-06-07 | Gruenenthal Gmbh | uso de agente farmacologicamente ativo e forma de dosagem farmacêutica |
| WO2013004462A1 (fr) | 2011-07-01 | 2013-01-10 | Fondazione Istituto Insubrico Di Ricerca Per La Vita | Complexe de tomoxiprole amorphe et de cyclodextrine présentant une vitesse de dissolution élevée et son procédé de préparation |
| US9308196B2 (en) | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
| US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
| US9855286B2 (en) | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
| US20130310435A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
| US8912226B2 (en) | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
| US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1196033B (it) * | 1984-02-22 | 1988-11-10 | Chiesi Farma Spa | Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche |
| IT1204725B (it) * | 1987-06-17 | 1989-03-10 | Edmond Pharma Srl | Complessi di inclusione del dipiridamolo con ciclodestrine |
| EP0518930A4 (en) * | 1990-03-02 | 1993-09-15 | Australian Commercial Research & Development Limited | Cyclodextrin compositions and methods for pharmaceutical and industrial applications |
| US5164379A (en) * | 1991-07-15 | 1992-11-17 | Bristol-Myers Company | Sucralfate/cyclodextrin complexes |
| IT1269578B (it) * | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
| DE19922572A1 (de) * | 1999-05-17 | 2000-11-23 | Bayer Ag | Verfahren zur Reinigung von organischen Isocyanaten, die so gereinigten organischen Isocyanate und ihre Verwendung |
-
2002
- 2002-06-17 ES ES02013251T patent/ES2286177T3/es not_active Expired - Lifetime
- 2002-06-17 EP EP02013251A patent/EP1374906B1/fr not_active Expired - Lifetime
- 2002-06-17 SI SI200230568T patent/SI1374906T1/sl unknown
- 2002-06-17 DE DE60219609T patent/DE60219609T2/de not_active Expired - Lifetime
- 2002-06-17 PT PT02013251T patent/PT1374906E/pt unknown
- 2002-06-17 AT AT02013251T patent/ATE359827T1/de active
-
2003
- 2003-06-12 CN CNB038173565A patent/CN100352444C/zh not_active Expired - Lifetime
- 2003-06-12 AU AU2003245931A patent/AU2003245931A1/en not_active Abandoned
- 2003-06-12 WO PCT/EP2003/006142 patent/WO2003105906A1/fr active IP Right Grant
- 2003-06-12 MX MXPA04012502A patent/MXPA04012502A/es active IP Right Grant
- 2003-06-12 PL PL373873A patent/PL218414B1/pl unknown
- 2003-06-12 US US10/516,945 patent/US7700579B2/en not_active Expired - Lifetime
- 2003-06-12 RU RU2004136988/15A patent/RU2316350C2/ru active
- 2003-06-12 KR KR1020047008384A patent/KR101079484B1/ko active IP Right Grant
- 2003-06-12 CA CA002489708A patent/CA2489708A1/fr not_active Abandoned
- 2003-06-12 EP EP03738016A patent/EP1513556B1/fr not_active Expired - Lifetime
- 2003-06-15 JO JO200367A patent/JO2533B1/en active
- 2003-06-16 TW TW092116236A patent/TWI341731B/zh not_active IP Right Cessation
- 2003-06-16 MY MYPI20032243A patent/MY134691A/en unknown
- 2003-07-27 SA SA03240220A patent/SA03240220B1/ar unknown
-
2004
- 2004-02-10 NO NO20040601A patent/NO332262B1/no not_active IP Right Cessation
- 2004-12-10 TN TNP2004000245A patent/TNSN04245A1/en unknown
- 2004-12-15 ZA ZA200410142A patent/ZA200410142B/xx unknown
- 2004-12-16 IL IL16579704A patent/IL165797A0/xx unknown
- 2004-12-16 HR HRP20041192AA patent/HRP20041192B1/hr not_active IP Right Cessation
- 2004-12-17 MA MA28012A patent/MA27367A1/fr unknown
-
2006
- 2006-01-13 HK HK06100587A patent/HK1080720A1/xx not_active IP Right Cessation
-
2007
- 2007-07-09 CY CY20071100907T patent/CY1107693T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI237024B (en) | A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor | |
| NO332262B1 (no) | Fremgangsmate for fremstilling av piroxicam: beta-cyklodekstrin-inklusjonsforbindelser | |
| EP2355805B1 (fr) | Complexes de rifaximin | |
| WO2014161131A1 (fr) | Préparation d'un complexe d'inclusion de méloxicam-β-cyclodextrine amorphe par l'intermédiaire d'un procédé de séchage par atomisation | |
| JP2008503495A (ja) | 薬剤共結晶組成物および関連した使用方法 | |
| EP1793862B1 (fr) | Procede pour la preparation des composes d'inclusion piroxicam: beta-cyclodextrine | |
| NO178456B (no) | Fremgangsmåte for fremstilling av farmasöytisk aktive piroksikam/syklodekstrinkomplekser | |
| EP0760680A1 (fr) | Compostion pharmaceutique | |
| Le et al. | Nanosized bicalutamide and its molecular structure in solvents | |
| TW201002654A (en) | Solid states of aliskiren free base | |
| Jaafar et al. | Preparation and physicochemical characterization of cocrystals for enhancing the dissolution rate of glimepiride | |
| US20120190662A1 (en) | Pharmaceutical propylene glycol solvate compositions | |
| Lin et al. | Thermodynamic study of grinding-induced loratadine inclusion complex formation using thermal analysis and curve-fitted FTIR determination | |
| JP2004519504A (ja) | 製薬活性剤の改良形態およびその製造方法 | |
| Pandya et al. | Formulation development of fast dispersible tablet of cefuroxime axetil | |
| Aragón-Aburto et al. | Characterization, stability and solubility of co-amorphous systems of glibenclamide and L-arginine at different pH | |
| KR20130010524A (ko) | 무정형 이트라코나졸의 제조방법 | |
| CZ299744B6 (cs) | Krystalická forma bezvodého 1S-[1alfa(2S*,3R*),9alfa]-6,10-dioxo-N-(2-ethoxy-5-oxotetrahydro-3-furanyl)-9-[[(1-izochinolyl)karbonyl]amino]oktahydro-6H-pyridazino[1,2-a][1,2]diazepin-1-karboxamidu a farmaceutická kompozice s jejím obsahem | |
| WO2004019989A1 (fr) | Compose d'inclusion a base de nateglinide | |
| MXPA00001713A (en) | New pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |